Publications by authors named "Arthur Sterin"

4 Publications

  • Page 1 of 1

Personalised treatment plan for children and adolescents with advanced haematological malignancies: a response to paediatric relapsed acute leukaemia: curative intent chemotherapy improves quality of life.

BMJ Support Palliat Care 2021 Apr 29. Epub 2021 Apr 29.

Pediatric Oncology and Hematology, Hôpital de la Timone, Marseille, Provence-Alpes-Côte d'Azur, France.

View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1136/bmjspcare-2021-003140DOI Listing
April 2021

Disseminated infection in an infant with CD40L deficiency.

IDCases 2021 7;24:e01115. Epub 2021 Apr 7.

IHU Méditerranée Infection, Marseille, France.

The protozoan affects the digestive tract of humans and animals. Cryptosporidiosis leads to diarrhoea mimicking a cholera-like course with dehydration and may even result in death in immunodeficient patients, as patients with hyper-IgM syndrome. We describe a rare case of disseminated infection in a seven- year-old boy with CD40 L deficiency. During the pre-graft phase, the patient presented an intestinal cryptosporidiosis which became complicated few days later during the aplasia period with a cholangitis and pulmonary cryptosporidiosis. was identified. After treatment with nitazoxanide and azithromycine the patient was doing well.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.idcr.2021.e01115DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8044382PMC
April 2021

Therapy-related acute myeloid leukemia following treatment of lymphoid malignancies.

Oncotarget 2016 Dec;7(52):85937-85947

Service d'Hématologie, Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse, France.

Therapy-related acute myeloid leukemia (t-AML) is a heterogeneous entity most frequently related to breast cancer or lymphoproliferative diseases (LD). Population-based studies have reported an increased risk of t-AML after treatment of lymphomas. The aim of this study was to describe the characteristics and outcome of 80 consecutive cases of t-AML following treatment of LD. t-AML accounted for 2.3% of all AML cases, occurred 60 months after LD diagnosis, and were characterized by a high frequency of FAB M6 AML and poor-risk cytogenetic abnormalities. Time to t-AML diagnosis was influenced by patient age, type of LD, and treatment. Among the 48 t-AML patients treated with intensive chemotherapy, median overall survival (OS) was 7.7 months compared to 26.1 months in de novo, 4.2 months in post-myeloproliferative neoplasm, 9.4 months in post-myelodysplastic syndrome, 8.6 months in post-chronic myelomonocytic leukemia AML, 13.4 months in t-AML secondary to the treatment of solid cancer, and 14.7 months in breast cancer only. OS of post-LD t-AML patients was significantly influenced by age, performance status, myelodysplastic syndrome prior to LD/t-AML, and treatment regimen for LD. Thus, t-AML following lymphoid malignancies treatment should be considered as very high-risk secondary AML. New treatment strategies in patients with LD/t-AML are needed urgently.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.13262DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5349887PMC
December 2016
-->